Growth Opportunities in Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics: Featuring Bluebird Bio, Atara, Perseo Pharma & More - ResearchAndMarkets.com
06 Dec 2022
ImmunotherapyOrphan DrugFast TrackGene TherapyClinical Study
DUBLIN--(BUSINESS WIRE)--The "Growth Opportunities in Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics" report has been added to ResearchAndMarkets.com's offering.
'Growth Opportunities in Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics'
This edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) focuses on advanced autologous and allogeneic cell therapies for cancers. It also covers developments in ADCs and small molecules for multiple cancers. Few innovations for inflammatory diseases and infectious diseases have also been highlighted in this issue. Therapies which leverage nanotechnology and engineered nanoparticles for drug protection and drug design complement these innovations. Synthetic biology innovations around low cost gene synthesis and deployment of gene circuits have been featured as well.
The Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry. The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.
The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.
Key Topics Covered:
Onco-Immunotherapy, Genetic Therapy, Synthetic Biology, Microbiome Therapeutics
Tumor Microenvironment Targeted Therapies With An Improved Therapeutic Index
Highly Selective Adc Platform
Bioatla - Investor Dashboard
Gene Therapies for Genetic Hematological Diseases
One-Time Curative Gene Therapy for Scd
Bluebird Bio - Investor Dashboard
Autologus Cell Therapy for Advanced Melanoma
Polyclonal Therapy Against Solid Tumors
Instil Bio, Inc. - Investor Dashboard
Immuno-Onco Therapies Against Solid Tumors
Car-T Cell Therapy With Enhanced Cell Proliferation
Bellicum Pharmaceuticals - Investor Dashboard
Allogeneic Cell Therapy Against Solid Tumors and Hematological Cancers
Off-The-Shelf Car T-Cell Therapy
Allogene Therapeutics - Investor Dashboard
Allogeneic T-Cell Therapy Without Gene Editing
Off-The-Shelf Ebv-Targeting T-Cell Products
Atara Bio - Investor Dashboard
Tumor Prilferation Targeting Oral Kinase Inhibitor
Small Molecule With Advanced Absorption, Distribution, Metabolism, and Excretion Properties
Zentalis Pharmaceuticals - Investor Dashboard
Macrophage Modifying Nanoparticle Platform With Anti Cancer Activity
Technology Modulating Multiple Cell Types
Nanotechnology-Protected Enzymes to Survive in the Gastrointestinal Environment
Enhancing Enzyme Delivery Through Nanotechnology
Perseo Pharma - Investor Dashboard
Gene Therapy for Treating Life-Threatening Liver Disorders
Single Administration Orphan Drug With Us Fast-Track Designation
Vivet Therapeutics - Investor Dashboard
Tailoring Cell Behavior With Precision
Genetic Circuits That Provide Accurate Control Over Gene Programming
Asimov - Investor Dashboard
Understanding Gut Microbiomes and Their Interactions to Formulate Therapeutic Products
Anti Inflammatory Live Biotherapeutics for Atopic Dermatitis
Siolta Therapeutics - Investor Dashboard
Gold Standard Customer Solution for Gene Synthesis
Benefits of Quick Turnover and Error-Free Sequencing
Eurofins Genomics Blue Heron - Investor Dashboard
Metabolism Boosting Daily Wellness Supplements With Anti-Aging Benefits
Nmn Causing Nad+ to Activate Sir2 Gene to Boost Metabolic Efficiency
Eh - Investor Dashboard
Point-Of-Care Device to Identify Bacteria in Urinary Tract Infections (Utis)
Rapid Assay Delivering Accurate Results Comparable to Laboratory Tests
Fq - Investor Dashboard
Technology Regulating Immune Cells
Immunotherapy Leading to Sustained Therapeutic Responses
Bacteriophage-Based Treatment for Antibiotic-Resistant Bacterial Lung Infection
National Jewish Health's Technology Value Proposition
Key Contacts
Companies Mentioned
Bioatla
Atara Bio
Asimov
EH
FQ
For more information about this report visit https://www.researchandmarkets.com/r/k1ljkq
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.